October 8, 2026
Managing severe, intractable chronic pain often requires advanced interventional solutions. Intrathecal drug delivery systems—commonly known as intrathecal pain pumps—deliver pain medication directly into the fluid surrounding the spinal cord.
While intrathecal pumps traditionally used opioid medications like morphine, modern pain management options include Ziconotide (Prialt): a non-opioid intrathecal medication designed to deliver profound pain relief without the risks of opioid tolerance, addiction, or systemic side effects.
Ziconotide is a synthetic class of medication derived from the natural peptide toxin of the Conus magus marine cone snail. It represents a completely distinct class of analgesics known as selective N-type voltage-gated calcium channel blockers.
Unlike opioids, which bind to mu-opioid receptors, Ziconotide works by blocking specific calcium channels located on the primary pain-transmitting nerve terminals within the dorsal horn of the spinal cord. By preventing these channels from opening, Ziconotide inhibits the release of pro-inflammatory neurotransmitters (such as substance P and glutamate), effectively stopping pain signals before they can travel up the spinal cord to the brain.
Utilizing Ziconotide within an intrathecal pain pump offers several distinct clinical benefits:
Ziconotide is primarily indicated for patients suffering from severe, chronic refractory pain—such as persistent failed back surgery syndrome, complex regional pain syndrome (CRPS), or severe neuropathic pain—who have failed conservative options or cannot tolerate oral pain medications.
Before permanent pump implantation, candidates undergo a temporary diagnostic trial to evaluate how effectively Ziconotide reduces pain levels and improves daily functional mobility.